Insmed Incorporated Stock

$104.17

0.40% yesterday

Nasdaq, Jul 17, 10:00 pm CET

ISIN

US4576693075

Symbol

INSM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Insmed Incorporated Stock price

$104.17

+77.69 293.39% 5Y

Nasdaq, Closing price Thu, Jul 17 2025

-0.42 0.40%

ISIN

US4576693075

Symbol

INSM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$19.9b

Enterprise Value

$19.8b

Net debt

positive

Cash

$1.2b

Shares outstanding

181.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

52.1 | 42.6

EV/Sales

52.0 | 42.5

EV/FCF

negative

P/B

200.4

Financial Health

Equity Ratio

14.1%

Return on Equity

-320.2%

ROCE

-54.9%

ROIC

Debt/Equity

11.4

Financials (TTM | estimate)

Revenue

$381.0m | $466.2m

EBITDA

$-854.0m | $-991.0m

EBIT

$-859.0m | $-969.8m

Net Income

$-1.0b | $-982.4m

Free Cash Flow

$-789.3m

Growth (TTM | estimate)

Revenue

20.8% | 28.2%

EBITDA

-26.4% | -26.8%

EBIT

-26.2% | -23.3%

Net Income

-35.7% | -7.5%

Free Cash Flow

-34.1%

EPS

$-5.6

FCF per Share

$-4.3

Short interest

6.9%

Employees

Rev per Employee

$290.0k

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Get Started for Free Today

Insmed Incorporated Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Insmed Incorporated forecast:

24x Buy

96%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Insmed Incorporated forecast:

Buy

96%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	381 381	21% 21% 100%
- Direct Costs	90 90	29% 29% 24%
Gross Profit	291 291	18% 18% 76%
- Selling and Administrative Expenses	516 516	44% 44% 135%
- Research and Development Expense	630 630	12% 12% 165%
EBITDA	-854 -854	26% 26% -224%
- Depreciation and Amortization	5.05 5.05	0% 0% 1%
EBIT (Operating Income) EBIT	-859 -859	26% 26% -225%
Net Profit	-1,013 -1,013	36% 36% -266%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Insmed Incorporated Stock News

Positive

MarketBeat

●

28 days ago

Russell Rebalance: 3 Stocks Ready to Move Higher

Investors pay close attention to the quarterly rebalancing of the S&P 500 index for good reason. First, the stocks in the S&P 500 make up approximately 80% of the total U.S. equity market.

Neutral

Forbes

●

about one month ago

Is Insmed Stock Overvalued After The 45% Jump?

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?

Neutral

PRNewsWire

●

about one month ago

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share.

More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office	United States
CEO	Will Lewis
Employees	1,271
Founded	1988
Website	insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now